echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > New progress has been made in the treatment of advanced ovarian cancer, and GEN-1 has achieved gratifying results in Phase I/II clinical trials!

    New progress has been made in the treatment of advanced ovarian cancer, and GEN-1 has achieved gratifying results in Phase I/II clinical trials!

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Ovarian cancer mainly occurs in women aged 50-70.


    Ovarian cancer

    Biopharmaceutical company Celsion today announced the latest information on the I/II OVATION 2 study of GEN-1 for the treatment of advanced ovarian cancer.


    immunity

    The OVATION 2 study explored the effectiveness and safety of GEN-1 combined with standard new adjuvant chemotherapy (NACT) in the treatment of newly treated stage III/IV ovarian cancer.


    The results of the OVATION 2 study showed that compared with the control group (standard of care only), the treatment group (standard of care + GEN-1) increased the patient’s progression-free survival by 33%.


    The results of the OVATION 2 study showed that compared with the control group (standard of care only), the treatment group (standard of care + GEN-1) increased the patient’s progression-free survival by 33%.


    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.